$IMUX
Immunic, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · New York, United States
IMUX chart
What traders are saying about $IMUX
Latest postsImmunic, Inc. news
- IMUX: December ENSURE readouts could position vidofludimus calcium for filing and a 2028 launch
TradingView ·
- Immunic at guggenheim conference: phase iii readout looms By Investing.com
Investing.com UK ·
- Immunic, Inc. expected to post a loss of 95 cents a share - Earnings Preview
TradingView ·
- Immunic (IMUX) Stock Price, Chart & Analysis
www.debelegger.nl ·
- Aberdeen Group plc Adds 266,034 Shares of Immunic Inc (IMUX) in Latest 13F Filing
GuruFocus ·
- Immunic (IMUX) Institutional Ownership 2026
MarketBeat ·
- Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
marketbeat.com ·
- IMUX: ProTEct-MS will test whether vidofludimus calcium can slow disability across progressive MS
TradingView ·
- Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development - Slideshow
Seeking Alpha ·
- IMUX: CALLIPER signals support a progressive-MS Phase 3 push, despite a missed primary endpoint
TradingView ·
- Arm falls 10% as modest revenue outlook fails to impress investors
Proactive financial news ·
- Immunic Announces Progressive MS R&D Day Webinar and Files Presentation with SEC on November 5, 2026
Kalkine Media ·
Immunic, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M |
| Diluted EPS | $-0.62 | $-1.00 | $-2.11 | $-3.78 |
| Total assets (year end) | $24.1M | $40.9M | $54.3M | $127.8M |
| Cash and equivalents (year end) | $15.5M | $35.7M | $46.7M | $106.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- 10-Q10-Q
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- DEF 14AProxy statement
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
- 8-KCurrent report (material event)
About Immunic, Inc.
- Ticker
- IMUX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1280776
- Former names
- VITAL THERAPIES INC
Frequently asked questions
What exchange is Immunic, Inc. listed on?
Immunic, Inc. trades on the Nasdaq under the ticker symbol IMUX.
What industry is Immunic, Inc. in?
Immunic, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Immunic, Inc. headquartered?
Immunic, Inc.'s business address on file with the SEC is in New York, United States.
When does Immunic, Inc.'s fiscal year end?
Immunic, Inc.'s fiscal year ends on December 31.